MTOR and Hepatic steatosis: RAPA administration exhibited significantly improved insulin resistance and hepatic steatosis in type 2 diabetes (T2DM) through inhibition of mTOR and alleviation of disorders of lipid metabolism (Zhou and Ye, 2018).